MONJUVI J Code: J9349

Drug & Product Overview

HCPCS Descriptor Injection, tafasitamab-cxix, 2 mg

HCPCS Added Date April 1, 2021

Manufacturer Incyte Corporation

Route of Administration Intravenous

Generic Status Single-Source; Branded

Dosage Type Single-Dose

Dosage Form Injection, Powder, Lyophilized, For Solution

About MONJUVI

Monjuvi is a medication aligned to the HCPCS J Code: J9349 for billing, pricing, and reimbursement purposes in the United States. It is an Oncology drug administered via the intravenous route and manufactured by Incyte Corporation.

According to CMS Drug Use Information: This medication is used to treat certain types of cancer (diffuse large B-cell lymphoma, follicular lymphoma). Tafasitamab belongs to a class of drugs known as monoclonal antibodies. It works by slowing or stopping the growth of cancer cells.

Disclaimer: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional.

NDC Code Information

Based on publicly available CMS files. The list of NDCs below is not exhaustive.

NDC Code	Drug	Manufacturer	Billing Units / Pkg	Package Size
50881-0013-03	Monjuvi	Incyte Corporation	100	200 MG / 5 ML
73535-0208-01	Monjuvi	Incyte Corporation	100	200 MG / 5 ML

Login for the full NDC crosswalk View pricing, complete NDC-to-HCPCS alignments, and package details.

Login →

MONJUVI Pricing & Reimbursement

J9349 Private Payer Reimbursement

$14.74 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →

Historical Graphing and Billing Calculator

per HCPCS unit

As of Q3 2026

MONJUVI Claims Performance

Claims from Jan 2026 – Aug 2026

Claim Denial Rate 10.91%

Avg. Days to File 8.2days

Avg. Days to Pay 24.8days

Real-world claims performance from FocalPoint, OnPoint Oncology's reimbursement analytics platform, with claims data accrued at the clearing house level.

Explore J9349 claims analytics on FocalPoint →

MONJUVI CPT Administration Codes

CPT Code	Description
96413	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
96415	Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)

JW / JZ modifiers apply

CMS has identified Monjuvi (J9349) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. Wastage billing guide →

MONJUVI Medically Unlikely Edits (MUE)

The most billing units of J9349 Medicare will pay for one patient in one day, as published by CMS. 1 unit = 2 mg.

Practitioner Office & Hospital Outpatient

900 units / day

= 1,800 mg per day

MAI 3 · Date of Service Edit: Clinical. Per-day limit based on clinical expectations; excess units are denied but may be appealed with documentation of medical necessity. See all MUE limits →

MONJUVI Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Relapsed or Refractory Diffuse Large B-cell Lymphoma Relapsed or Refractory Follicular Lymphoma Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma

Frequently Asked Questions

Is there an available Monjuvi billing and coding guide?

Billing and coding information for MONJUVI can be found through Incyte Corporation. Visit Here →

Are there any available Monjuvi patient assistance programs?

MONJUVI patient assistance information can be found through Morphosys. Visit Here →

Where can I find Monjuvi prescribing information?

MONJUVI prescribing information can be found at the link below: Visit Here →

Where can I find Monjuvi side effect information?

Information regarding MONJUVI's side effects can be found at MedlinePlus Visit Here →

Does billing MONJUVI require JZ/JW wastage modifiers?

CMS has identified MONJUVI(J9349) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. See CMS guidelines on use of the JZ and JW wastage modifiers below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.